Plain-English translation of NCT02393157 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for young people whose B-cell lymphoma (a type of blood cancer) has come back or didn't respond to their first treatment. The combination includes , a new antibody medication, paired with three chemotherapy drugs (, , and ). Researchers want to see if adding this medication to the chemotherapy regimen helps more patients respond to treatment and understand how safe this combination is.
When lymphoma returns or doesn't respond to initial treatment, the outlook becomes more challenging and patients need stronger options. This trial is designed to test whether this new medication, combined with existing chemotherapy, can improve how many patients achieve remission and give young people with relapsed lymphoma a better chance at recovery.
You likely qualify if…
You likely don't qualify if…
You would receive a 'pre-phase' of treatment with the new medication given intravenously over several days, followed by multiple 3-week treatment cycles combining the medication with chemotherapy drugs (also given intravenously). Depending on whether your cancer has involved your central nervous system, you may also receive additional protective medication. Throughout the trial, you'll have regular blood tests and imaging scans to monitor how well the treatment is working and track any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States